Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Arch Gen Psychiatry. 2009 Nov;66(11):1253–1262. doi: 10.1001/archgenpsychiatry.2009.142

Table 2.

CO-confirmed point-prevalent abstinence and initial cessation rates (%)

Placebo Bupropion Lozenge Patch Bupropion
+
Lozenge
Patch
+
Lozenge
Initial cessation* 69.4 82.2 81.3 87.7 84.5 91.5
1 week 23.3 34.5 29.2 40.5 37.4 43.4
8 weeks (end of
treatment)
30.2 40.2 40.4 44.7 50.4 53.6
6-months 22.2 31.8 33.5 34.4 33.2 40.1
*

Initial cessation is defined as at least 1 day of abstinence during the first 7 days after the target quit day. Due to missing data n = 1424 for this analysis.